Expertise in
53
conditions

Dr. Gregory M. Enns

Medical Genetics | Pediatrics
Lpch Medical Group Div Of Lucile
725 Welch Rd, 
Palo Alto, CA 
Accepting New Patients
Offers Telehealth
Expertise in
53
conditions
Lpch Medical Group Div Of Lucile
725 Welch Rd, 
Palo Alto, CA 

Overview

Gregory Enns is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Palo Alto, California.

Dr. Enns is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Urea Cycle Disorders (UCD), Methylmalonic Acidemia, Arginase Deficiency, and Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency.

He is actively involved in clinical research, co-authoring 121 peer reviewed articles and participating in 7 clinical trials. Dr. Enns is currently accepting new patients.

Specialties

Medical Genetics
Pediatrics

Licenses

Medical Biochemical Genetics in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

LPCH MEDICAL GROUP DIV OF LUCILE
725 Welch Rd, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drug: PEG-Zilarginase
Study Phase: Phase 3
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
Enrollment Status: Active_not_recruiting
Publish Date: June 23, 2026
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Enrollment Status: Terminated
Publish Date: March 31, 2026
Intervention Type: Other, Drug
Study Drug: Vatiquinone
Study Phase: Phase 2/Phase 3
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
An Open-label, Multicentre Extension Study to Evaluate the Long-Term Safety, Tolerability and Effects of Intravenous AEB1102 in Patients With Arginase I Deficiency Who Previously Received Treatment in Study CAEB1102-101A
An Open-label, Multicentre Extension Study to Evaluate the Long-Term Safety, Tolerability and Effects of Intravenous AEB1102 in Patients With Arginase I Deficiency Who Previously Received Treatment in Study CAEB1102-101A
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Drug: AEB1102
Study Phase: Phase 2
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

120 Total Publications

The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease.
The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease.
Journal: medRxiv : the preprint server for health sciences
Published: June 29, 2026
Similar Doctors
Expertise in
100
conditions
Dr. David A. Stevenson
Medical Genetics | Pediatrics
Expertise in
100
conditions
Dr. David A. Stevenson
Medical Genetics | Pediatrics
Referral may be required

Lpch Medical Group Div Of Lucile

725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-498-7200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Stevenson is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Palo Alto, California. Dr. Stevenson is highly rated in 100 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Neurofibromatosis Type 1 (NF1), RASopathies, Costello Syndrome, and Deep Brain Stimulation.

Expertise in
137
conditions
Dr. Dena R. Matalon
Medical Genetics | Pediatrics
Expertise in
137
conditions
Dr. Dena R. Matalon
Medical Genetics | Pediatrics
Referral may be required

Lpch Medical Group Div Of Lucile

725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-498-7200
Languages Spoken:
English
See accepted insurances

Dena Matalon is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Palo Alto, California. Dr. Matalon is highly rated in 137 conditions, according to our data. Her clinical expertise encompasses Campomelia Cumming Type, Microcephaly, Microcephaly Deafness Syndrome, and Coffin-Lowry Syndrome.

Expertise in
9
conditions
Dr. Svetlana A. Yatsenko
Medical Genetics
Expertise in
9
conditions
Dr. Svetlana A. Yatsenko
Medical Genetics
Referral may be required
300 Pasteur Dr, 
Stanford, CA 
 (0.2 miles away)
650-723-4000
Languages Spoken:
English

Svetlana Yatsenko is a Medical Genetics provider practicing medicine in Stanford, California. Dr. Yatsenko is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Mosaicism, Turner Syndrome, Intersex, 46XX Testicular Disorder of Sex Development, and Hormone Replacement Therapy (HRT).

Frequently Asked Questions about Dr. Gregory M. Enns

How do I make an appointment with Dr. Gregory M. Enns?

You can book an appointment with Dr. Gregory M. Enns by calling their office at 650-498-7200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gregory M. Enns a top-rated expert for Urea Cycle Disorders (UCD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gregory M. Enns is classified as an Elite expert for Urea Cycle Disorders (UCD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gregory M. Enns specialize in?

While Dr. Gregory M. Enns is a Medical Genetics, they have specific expertise in Urea Cycle Disorders (UCD), Methylmalonic Acidemia, and Arginase Deficiency. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Medical Genetics.

Does Dr. Gregory M. Enns participate in research or clinical trials?

Yes. Dr. Gregory M. Enns has published 120 articles and abstracts on conditions like Urea Cycle Disorders (UCD). You can view a list of Dr. Gregory M. Enns's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gregory M. Enns accept my insurance?

Dr. Gregory M. Enns accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 650-498-7200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Enns's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 39 Advanced Conditions
View All 127 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile